Nontuberculous Mycobacteria
Nontuberculous Mycobacteria Market

Nontuberculous Mycobacteria Infection (NTM) is caused because of the nontuberculous mycobacteria, which is ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy persons and those with compromised immune systems.


Nontuberculous Mycobacteria Infection lung disease often affects older adults with chronic lung disease and may be a manifestation of a complex genetic disorder that is determined by interactions among multiple genes, as well as environmental exposures.  


Nontuberculous Mycobacteria Infection Epidemiological Segmentation 

The Epidemiological Segmentation of Nontuberculous Mycobacteria Infection in 7MM from 2017 to 2030 is segmented as:- 

  • Total prevalent cases of Nontuberculous Mycobacteria Infection 
  • Diagnosed prevalent cases of Nontuberculous Mycobacteria Infection 
  • Diagnosed prevalent cases of Nontuberculous Mycobacteria Infection by species
  • Diagnosed prevalent cases of Nontuberculous Mycobacteria Infection by severity
  • The treatable population of Nontuberculous Mycobacteria Infection 


Nontuberculous Mycobacteria Infection Epidemiology 

  • The total prevalent population of Nontuberculous Mycobacteria infections in the 7MM will be 395,429 cases by 2030.
  • The United States accounts for approximately 49% of total prevalent cases in 7MM.


Nontuberculous Mycobacteria Infection Market

The therapeutic market of Nontuberculous Mycobacteria Infection in 7MM is growing at a CAGR of 6.6% for the study period.  


Nontuberculous Mycobacteria Infection Market Drivers

  • Increasing Demand for Therapeutic Products
  • Increasing prevalence
  • Impending Opportunities in the Market
  • Increasing Spending on Branded Drugs


Nontuberculous Mycobacteria Infection Market Barriers

  • Lack of Funding and R&D activities
  • Lack of awareness
  • Lack of Disease Understanding
  • Future competition

 

Nontuberculous Mycobacteria Infection Emerging Drugs

The emerging drugs of the Nontuberculous Mycobacteria Infection market are 

  • Arikayce
  • RHB-204
  • Thiolanox
  • Molgradex
  • Nitric Oxide

And many others.  


Nontuberculous Mycobacteria Infection Key Players

The key players in the Nontuberculous Mycobacteria Infection market are

  • Insmed Incorporated
  • RedHill Biopharma
  • Novoteris
  • Savara
  • Beyond Air

And many others.